Drugs / 64Cu-LNTH-1363S
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06298916 | Aug → Nov 2025 overdue | colorectal cancer, esophageal cancer, gastric cancer, malignant pancreatic neoplasm +1 | Lantheus Medical Imaging | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 64Cu-LNTH-1363S | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06298916 ↗ |
| Action | Inhibit | “FAP inhibitor” NCT06298916 ↗ |
| Modality | Diagnostic / imaging agent | “radiolabeled with Copper-64 (64Cu) for PET/CT Imaging” NCT06298916 ↗ |